Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-5849

6 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 50090-5849). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Biso Api Structure (Api Pic New1)

Biso Api Structure (Api Pic New1)
Chemical structure diagram of Bisoprolol Fumarate and Hydrochlorothiazide showing molecular connectivity and functional groups.*
FDA Label Image

Hctz Api Structure (Api Pic New2)

Hctz Api Structure (Api Pic New2)
Chemical structure diagram of Bisoprolol Fumarate, showing atomic connections and functional groups clearly associated with this active ingredient.*
FDA Label Image

1 (Table1 New)

1 (Table1 New)
A data table presenting the mean decrease in sitting systolic/diastolic blood pressure (mm Hg) and heart rate (bpm) after 3 to 4 weeks from two clinical studies. It compares placebo and different dosage groups of Bisoprolol Fumarate and Hydrochlorothiazide, showing total changes and drug effects in blood pressure and heart rate.*
FDA Label Image

1 (Table 2new)

1 (Table 2new)
A data table showing the percentage of patients experiencing various adverse events in a clinical study. It compares incidences between Placebo and Bisoprolol Fumarate and Hydrochlorothiazide 5/6.25 mg tablet groups, detailing overall and drug-related events across body systems such as cardiovascular, respiratory, central nervous system, musculoskeletal, psychiatric, and gastrointestinal.*
FDA Label Image

1 (Table 3new)

1 (Table 3new)
A data table titled 'Serum Potassium Data from U.S. Placebo Controlled Studies' comparing potassium mean change (mEq/L) and hypokalemia percentage across different groups: Placebo (N=130), Bisoprolol Fumarate and Hydrochlorothiazide 2.5/6.25 mg (N=28), Bisoprolol 5/6.25 mg (N=149), Bisoprolol 10/6.25 mg (N=28), and Hydrochlorothiazide 25 mg (N=142). It shows mean potassium change ranging from -0.30% to +0.11 and hypokalemia rates from 0.0% to 5.5%.*
FDA Label Image

Label Image (Lbl500905849)

Label Image (Lbl500905849)
Label for Bisoprolol Fumarate and Hydrochlorothiazide 5 mg/6.25 mg film-coated tablets, manufactured by A-S Medication Solutions. The label includes storage instructions to keep at 68 to 77 degrees Fahrenheit and states the package contains 30 tablets. The product NDC is 50090-5849.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.